Mamwe mashoko ― Shona

Urticaria inowanzo ratidza nekukwenya kwakasimudzwa welts. Dzimwe nguva inoperekedzwa nekuzvimba kwemukati matissue. Kurapa kunonyanya kusanganisira kudzivirira zvinokonzeresa, kana zvichizivikanwa. Mushonga wekutanga unosanganisira antihistamines matsva, anogona kugadziridzwa kusvika kumazinga akakwirira kana zvichidikanwa. Mimwe mishonga yakaita seyakare antihistamines, H2 blockers, leukotriene receptor antagonists, antihistamines yakasimba, uye makosi mapfupi e‑corticosteroids anogona kuwedzerwa sekutsigira kwakawedzerwa. Muzviitiko apo urticaria isingapinduri matanho aya, varwere vanogona kutumirwa kuna nyanzvi kuti vawane mamwe marapirwo akadai se‑omalizumab kana cyclosporine.
Urticaria commonly presents with intensely itchy raised welts. It is sometimes accompanied by swelling of the underlying tissues. Treatment primarily involves avoiding triggers, if known. First-line medication includes newer antihistamines, which can be adjusted to higher doses if needed. Other medications like older antihistamines, H2 blockers, leukotriene receptor antagonists, stronger antihistamines, and short courses of corticosteroids can be added as extra support. In cases where urticaria persists despite these measures, patients might be referred to specialists for additional therapies such as omalizumab or cyclosporine.

Ongororo iyi inotsanangura nhungamiro yazvino yekurapa urticaria uye inopa kunzwisisa kutsva kwezvikonzero zvayo.
This review outlines the latest guidelines for treating urticaria and offers new understandings of its causes.

Second-generation H1-antihistamines (e.g., cetirizine, loratadine, fexofenadine), Omalizumab, Ciclosporin, and short courses only of systemic corticosteroids